IONIS PHARMACEUTICALS INC (IONS) stock intrinsic value fair value estimate & owner earnings analysis

Ionis Pharmaceuticals is a Carlsbad, California drug developer built on antisense chemistry - short strands of synthetic RNA-like material that switch off the production of disease-causing proteins. For most of its history it earned money by licensing medicines to larger partners: SPINRAZA for spinal muscular atrophy (sold by Biogen, about $212 million of royalties to Ionis in 2025) and WAINUA for a hereditary nerve disease (sold with AstraZeneca, about $49 million of royalties in 2025) are the two that matter most today. It is now in the middle of turning itself into a company that sells its own medicines in the United States: TRYNGOLZA (olezarsen) for very high triglycerides, approved for the rare genetic form in December 2024 and for the much larger severe hypertriglyceridemia population in late June 2026; DAWNZERA for hereditary angioedema, launched in 2025; and ZANVASTRO (zilganersen) for Alexander disease, approved in September 2026. What the business has earned. Measured as the cash left for owners after paying staff in stock, maintaining its facilities, and stripping out timing swings in working capital, Ionis has lost money in seven of the last ten years. The ten-year median is a loss of about $0.70 a share and the last four years have all been losses of $2.46 to $3.12 a share (2025: a loss of about $394 million, or $2.46 a share, on revenue of $944 million). Stock compensation of $100-230 million a year is a real cost that we deduct. The one strong year, 2019, came from recognizing large partner payments received earlier. The first half of 2026 was worse than 2025 - about $346 million of owner cash consumed in six months - as selling costs rose for three launches. There is no historical earnings level to anchor a valuation on, so each case is built forward from the specific revenue streams that exist today. What changed since our previous look. Two things moved the picture. Positively, the severe hypertriglyceridemia approval and the ZANVASTRO approval both happened, so those launches are now real products rather than hopes. Negatively, on September 4, 2026 Novartis reported that the pelacarsen Lp(a)HORIZON outcomes trial in 8,323 patients failed to reduce heart attacks and strokes; we no longer give that program any value, and it also lowers the cap on what Royalty Pharma takes from SPINRAZA royalties. Ionis also cut the net price of TRYNGOLZA from April 1, 2026 to broaden access, which took second-quarter TRYNGOLZA sales down to about $5 million despite rising patient demand. The previous figures were built on a different basis and are not comparable. How the cases are built. Every case values only what exists today: SPINRAZA royalties (with Royalty Pharma taking 25% through 2027 and 45% from 2028 until it has collected its capped amount), WAINUA royalties, a small tail of other royalties, and the three launched products. The large research pipeline - including the partnered hepatitis B drug bepirovirsen awaiting an October 26, 2026 decision - is given no value in the base or bear case, because nothing that has not yet been approved is in the bag. We treat Ionis's research engine as roughly self-funding from partner payments, which have run at $330-470 million a year for many years, and credit it with no net value. Management's target of break-even cash flow in 2028 is not used as an input. Base case, about $7.63 a share. Owner cash keeps draining through 2028 (about $1.1 billion from today) as the three launches are built out, then the business settles at roughly $200-230 million a year of cash before interest from 2029: products holding around $330 million of annual sales (close to the run rate already reached in the second half of 2026), SPINRAZA royalties declining slowly and then eroding about 15% a year from 2030 as newer spinal muscular atrophy treatments take share, and WAINUA royalties flat at about $70 million until around 2034. Everything fades after the mid-2030s as exclusivity runs out and nothing named replaces it. The business is worth about $380 million on that path. Ionis holds about $2.05 billion of cash and investments against $1.35 billion of convertible notes ($575 million at 1.75% due June 2028 and $770 million at 0% due December 2030) and a small mortgage. Because the notes carry interest far below a normal borrowing cost, their true burden is about $200 million less than face value. Adding the business to net cash of roughly $890 million gives about $1.27 billion, or $7.63 a share. Most of that value is the cash, not the operations. Bear case, about -$1.53 a share. The launches stall at about $220 million of combined sales, the sales force cannot be cut fast enough, and burn runs about $1.4 billion through 2028. SPINRAZA erodes 20% a year from 2029 and WAINUA fades from 2033. After repaying the 2028 notes, Ionis would not have the cash to repay the $770 million 2030 notes and would have to refinance them at a much higher rate or issue shares at a depressed price - the same pattern biotech companies went through in the 2022 funding downturn. The business in this case is worth about -$820 million against about $570 million of net cash after the refinancing cost: the company would owe roughly $250 million more than it is worth, meaning current shareholders would be heavily diluted. Bull case, about $31.28 a share. TRYNGOLZA in severe hypertriglyceridemia and DAWNZERA execute well, combined product sales reach about $900 million by 2031 and hold until the late 2030s, bepirovirsen is approved on schedule and pays a growing royalty, and the business reaches break-even in 2028 as management plans. The business is worth about $4.3 billion plus $890 million of net cash. The margin-of-safety price. How sure are we of the earnings level? Not very: there is no stable history, and the outcome depends on launches that are months old, at a price for TRYNGOLZA that was just reset, against a well-funded competitor (Arrowhead's plozasiran) in the same triglyceride market. The worst plausible outcome is the bear case: launches disappoint while the company is still spending at full rate, and the 2030 notes force a dilutive financing. The structure would survive - the cash covers the 2028 notes and there is no near-term going-concern issue - but shareholders could own a much smaller share of a modest royalty business. If we are wrong about launch uptake, about how fast spending can be cut, and about SPINRAZA's erosion, the value moves anywhere from below zero to the low $30s. The shares pay no dividend, so the return depends entirely on the business proving itself; the price assumes a holding period of roughly three to five years. The margin-of-safety price of $3.50 a share is less than the roughly $4.10 a share of cash left after all debt, so the price assigns no value to the royalty streams and three approved products, and the cash cushion absorbs a good part of the bear-case burn; if the base case plays out over about four years the shares would be worth roughly double. Above that price the valuation would depend on launch success the evidence does not yet support.